Merck & Co., Inc. (MRK)

73.00
0.19 0.26
NYSE
Prev Close 73.19
Open 73.16
Day Low/High 72.74 / 73.81
52 Wk Low/High 52.83 / 81.29
Volume 6.74M
Exchange NYSE
Shares Outstanding 2583.07B
Market Cap 189.06B
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Why are big institutions running and can you outrace them?

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'

Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon

The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.

The Technical Oracle of Delphi Says Merck Could Go Up or Down

The Technical Oracle of Delphi Says Merck Could Go Up or Down

How do the charts and indicators look ahead of their quarterly release?

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Merck Is My Top Stock Pick for 2019

Merck Is My Top Stock Pick for 2019

People will still take their medicine regardless of the state of the economy.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous

Use it to your advantage or don't use it at all.

3 Tips for Trading the Fed's More Dovish Stance

3 Tips for Trading the Fed's More Dovish Stance

Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck is vey overbought on a number of time frames.

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck shares retreat as regulatory approval ramps up speculation.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.